Bayer, Sun Pharma sign marketing and distribution agreement for second brand of Finerenone in India
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Microdosing has emerged as a key trend in the pharmaceutical and nutritional markets
Lays foundation stone of NIPER Hyderabad and NIPER Raebareli
Varenicline Tablets (RLD Chantix) had estimated annual sales of US $412 million in the US
The three-day forum will feature global leaders, scientists, regulatory body representatives, industry associations, and academia among many others
Atlas AI combines NVIDIA BioNeMo cloud APIs for intelligent chemical and protein design
Signs MoU with the Govt. of Gujarat at Vibrant Gujarat Summit
Launch innovative vitamin sublingual sprays
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
Subscribe To Our Newsletter & Stay Updated